Paragon Capital Management Inc. Buys 53,937 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Paragon Capital Management Inc. grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 328.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,339 shares of the biopharmaceutical company's stock after acquiring an additional 53,937 shares during the quarter. Royalty Pharma comprises 1.4% of Paragon Capital Management Inc.'s holdings, making the stock its 18th largest holding. Paragon Capital Management Inc.'s holdings in Royalty Pharma were worth $1,794,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Swedbank AB grew its holdings in Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after buying an additional 1,136,800 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock worth $84,915,000 after acquiring an additional 1,103,341 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company's stock worth $85,809,000 after purchasing an additional 936,900 shares during the period. Point72 Asset Management L.P. bought a new position in Royalty Pharma in the 3rd quarter worth about $14,898,000. Finally, Geode Capital Management LLC boosted its stake in Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock worth $205,562,000 after purchasing an additional 417,490 shares during the period. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Trading Up 1.1 %

Shares of RPRX traded up $0.33 during mid-day trading on Friday, hitting $31.73. 3,393,389 shares of the company's stock traded hands, compared to its average volume of 4,435,420. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $32.21. The firm has a market capitalization of $18.69 billion, a P/E ratio of 16.44 and a beta of 0.49. The business's 50-day moving average price is $27.83 and its 200-day moving average price is $27.65.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be given a dividend of $0.22 per share. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.77%. Royalty Pharma's payout ratio is currently 43.52%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RPRX. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. Finally, Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.